7 Best Peptides for Weight Loss in 2026: Ranked by Clinical Results

The best peptides for weight loss in 2026 range from blockbuster GLP-1 drugs delivering nearly 15% body-weight reduction to cutting-edge triple agonists that obliterate fat stores at rates never seen before in clinical trials. If you've been sifting through generic listicles that lump semaglutide and collagen peptides in the same article, this guide is the corrective. We've ranked seven research-backed peptides strictly by efficacy data, mechanism strength, and real-world usability — so you know exactly where each one stands before you commit to a protocol.

How We Ranked These Peptides

Every peptide on this list was evaluated against four criteria:

• Clinical efficacy: Percentage of body weight lost in controlled trials vs. placebo
• Mechanism: How specifically does it target fat loss pathways?
• Dosing practicality: Injection frequency, dose titration complexity, and tolerance
• Risk profile: Known side effects, contraindications, and long-term safety data

Rankings are ordered from highest clinical weight-loss efficacy to lowest. Not every peptide here is FDA-approved — some are research compounds used by physicians off-label or available for research purposes only. We've noted regulatory status clearly for each one. Use our peptide dose calculator to estimate protocols based on your body weight.

Ranked Comparison: Best Peptides for Weight Loss (2026)

#1 — Retatrutide: The Triple Agonist Rewriting the Weight Loss Ceiling

Retatrutide is the most powerful weight-loss peptide ever tested in human trials. A phase 2 trial published in The New England Journal of Medicine (2023) reported a mean body-weight reduction of 28.7% at 48 weeks in patients receiving the 12 mg dose — a number that would have seemed impossible five years ago. To put that in perspective: a 250 lb person could realistically expect to lose over 70 lbs on retatrutide, compared to roughly 37 lbs on semaglutide.

What drives that performance is the compound's triple agonism: it activates GLP-1 (appetite suppression, slowed gastric emptying), GIP (enhanced insulin sensitivity, adipocyte fat release), and glucagon receptors (direct hepatic fat burning and increased energy expenditure). No other approved or near-approved peptide hits all three axes simultaneously.

Retatrutide Clinical Data

• Phase 2 RCT (NEJM, 2023): 338 adults, BMI 30–50 kg/m²
• 12 mg dose: 28.7% mean weight loss at 48 weeks
• 4 mg dose: 17.5% | 8 mg dose: 24.2%
• 91% of participants achieved ≥5% weight loss at the highest dose
• Phase 3 trials (TRIUMPH program) underway; FDA approval expected 2026–2027

Retatrutide Dosage

Phase 2 protocol: Start at 2 mg once weekly, titrate every 4 weeks through 4 mg, 8 mg, and 12 mg over 24 weeks. The slow titration significantly reduces nausea risk. See the full Retatrutide dosing guide for titration schedules and missed-dose protocols.

Pros & Cons

• ✅ Highest documented weight loss of any peptide in human trials
• ✅ Once-weekly injection — high compliance
• ✅ Significant visceral fat reduction alongside total weight loss
• ❌ Not yet FDA-approved (phase 3 ongoing)
• ❌ Only available through research channels or international clinical access
• ❌ Nausea/vomiting during titration phase (mitigated by slow ramp-up)

Best for: Individuals with significant obesity (BMI ≥30) who have not responded adequately to semaglutide or tirzepatide, or those who want maximum efficacy and are prepared for research-compound sourcing.

#2 — Tirzepatide: The Dual Agonist with Proven FDA Approval

Tirzepatide (brand name: Zepbound for obesity, Mounjaro for diabetes) is the strongest FDA-approved weight-loss peptide as of 2026. Its dual mechanism — activating both GLP-1 and GIP receptors — gives it a meaningful edge over pure GLP-1 agonists like semaglutide. The SURMOUNT-1 trial, published in NEJM (2022), enrolled 2,539 non-diabetic adults with obesity and tracked them for 72 weeks.

Tirzepatide Clinical Data

• SURMOUNT-1 (NEJM, 2022): 2,539 participants, 72 weeks
• 15 mg dose: 20.9% mean weight loss vs. 3.1% placebo
• 10 mg dose: 19.5% | 5 mg dose: 15.0%
• 57% of 15 mg group achieved ≥20% weight loss
• FDA-approved for chronic weight management (Zepbound) since November 2023

Tirzepatide Dosage

Standard protocol: 2.5 mg once weekly for 4 weeks → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg. Titration is dictated by tolerability. Most clinical weight-loss protocols aim for the 10–15 mg maintenance range. Compare tirzepatide vs. semaglutide side-by-side for a full breakdown of which drug wins at each dose tier.

Pros & Cons

• ✅ FDA-approved — highest regulatory confidence
• ✅ Superior weight loss vs. semaglutide in head-to-head studies
• ✅ Proven cardiovascular and glycemic benefits
• ✅ Widely available through telehealth and endocrinology clinics
• ❌ GI side effects (nausea, diarrhea, vomiting) common during titration
• ❌ Expensive without insurance coverage
• ❌ Weight regain common if discontinued without lifestyle changes

Best for: Anyone who wants the best FDA-approved option with the highest likelihood of sustained ≥15% weight loss. Particularly effective for individuals with type 2 diabetes or insulin resistance alongside obesity.

#3 — Semaglutide: The Gold Standard GLP-1 with a Decade of Data

Semaglutide (Wegovy, Ozempic) is the most widely prescribed peptide for weight loss globally, and for good reason: it consistently delivers ~14.9% body-weight reduction in the landmark STEP 1 trial (NEJM, 2021) — nearly six times the placebo result. While it now ranks third behind retatrutide and tirzepatide purely on efficacy numbers, semaglutide's safety profile is the most thoroughly characterized of any weight-loss peptide, with data from millions of real-world patients.

Semaglutide Clinical Data

• STEP 1 Trial (NEJM, 2021): 1,961 adults with obesity, 68 weeks
• 2.4 mg weekly: 14.9% mean weight loss vs. 2.4% placebo
• 86.4% achieved ≥5% weight loss | 69.1% achieved ≥10% | 50.5% achieved ≥15%
• SELECT trial (NEJM, 2023): 20% reduction in cardiovascular events vs. placebo

Semaglutide Dosage

Starting dose: 0.25 mg once weekly for 4 weeks, then titrate by 0.25 mg every 4 weeks to target 2.4 mg. Ozempic (diabetes label) maxes at 2.0 mg; Wegovy (obesity label) reaches 2.4 mg. Both are once-weekly subcutaneous injections.

Pros & Cons

• ✅ Largest real-world safety dataset of any weight-loss peptide
• ✅ FDA-approved, widely covered by insurance
• ✅ Proven cardiovascular risk reduction
• ✅ Available through dozens of telehealth providers
• ❌ Lower ceiling than tirzepatide or retatrutide
• ❌ GI side effects persist in 30–40% of patients
• ❌ Weight regain on discontinuation without lifestyle anchor

Best for: First-line peptide therapy for weight loss, particularly for patients new to GLP-1 agonists, those with established cardiovascular risk, or anyone seeking the best-characterized safety profile. Read our full tirzepatide vs. semaglutide comparison to decide which GLP-1 option fits your profile.

#4 — CJC-1295 + Ipamorelin: The GH Secretagogue Stack for Body Recomposition

The CJC-1295 + Ipamorelin stack is the most popular research-peptide combination for fat loss paired with lean muscle preservation. Unlike GLP-1 drugs that work primarily through appetite suppression, this stack stimulates your pituitary gland to release natural growth hormone (GH) in pulses that mirror the body's own nocturnal GH surges — driving lipolysis (fat breakdown) while preserving or building muscle tissue simultaneously.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors and dramatically extends the half-life of each GH pulse. Ipamorelin is a selective GH secretagogue that mimics ghrelin without the appetite stimulation or cortisol spike associated with older secretagogues like GHRP-6. Together, they produce a synergistic GH release roughly 3–5× greater than either peptide alone.

CJC-1295 + Ipamorelin Clinical Context

• CJC-1295 (2 mg, single dose): Sustained GH elevation for 6+ days vs. 2-hour window with native GHRH
• Combination protocols in clinical settings report body fat reductions of 8–12% over 12–24 weeks alongside lean mass increases
• Particularly effective at reducing visceral abdominal fat alongside subcutaneous fat
• IGF-1 increases of 20–30% documented in multiple small studies

CJC-1295 + Ipamorelin Dosage

Standard protocol: CJC-1295 (without DAC): 100–300 mcg + Ipamorelin: 100–300 mcg, injected subcutaneously 1–2× daily (ideally 30–60 min before sleep and optionally pre-workout). Run in cycles of 12 weeks on, 4 weeks off. Use our dose calculator to adjust for body weight.

Pros & Cons

• ✅ Preserves and builds lean muscle while burning fat
• ✅ Improves sleep quality and recovery
• ✅ No significant appetite suppression (good for athletes in surplus)
• ✅ Relatively mild side effect profile
• ❌ Requires daily injections (2× per day for best results)
• ❌ Research compound — not FDA-approved for weight loss
• ❌ Slower fat loss than GLP-1 drugs; best results at 12–24 weeks
• ❌ Water retention in first 2–4 weeks

Best for: Athletes, gym-goers, and fitness enthusiasts who want to lose fat without losing muscle, or who can't tolerate GLP-1-related GI side effects. Excellent as a complement to resistance training. See also our full peptides for fat loss guide.

#5 — Tesamorelin: The Visceral Fat Specialist

Tesamorelin is a synthetic GHRH analogue that's FDA-approved under the brand name Egrifta SV — specifically for reducing excess visceral abdominal fat in HIV-positive patients with lipodystrophy. Outside that approved indication, it's increasingly used off-label by physicians addressing metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and visceral obesity in the general population.

Where tesamorelin shines is in its precision. Multiple placebo-controlled trials show it selectively reduces visceral adipose tissue (VAT) — the metabolically dangerous deep abdominal fat linked to heart disease, insulin resistance, and type 2 diabetes — by 10–15% without the dramatic suppression of appetite seen with GLP-1 drugs. This makes it ideal for patients who are near-normal weight but carrying dangerous visceral fat loads.

Tesamorelin Clinical Data

• Pivotal HIV-lipodystrophy RCTs: VAT reduction of ~15% vs. placebo at 26 weeks
• NAFLD trials: significant liver fat reduction (hepatic lipid content ↓ 18% vs. placebo)
• IGF-1 increase: 181 µg/L above baseline on average
• Trunk fat reduced by an average of 400 cm² (cross-sectional area) in pivotal trials

Tesamorelin Dosage

Standard protocol: 2 mg subcutaneous injection once daily, preferably at the same time each day. No titration required. 26-week minimum protocol recommended to assess visceral fat response.

Pros & Cons

• ✅ FDA-approved — highest regulatory confidence among research-adjacent peptides
• ✅ Precise visceral fat reduction with less total weight change
• ✅ Proven liver fat reduction — valuable for NAFLD
• ✅ Once-daily dosing
• ❌ Less total weight loss than GLP-1 agonists
• ❌ Associated with elevated IGF-1 — theoretical cancer concern with long-term use
• ❌ Daily injection required
• ❌ Off-label use in non-HIV populations limits reimbursement

Best for: Metabolically unhealthy individuals with high visceral fat but moderate total BMI, or those with NAFLD looking to reduce liver fat. Also valuable as an add-on to GLP-1 therapy when residual visceral fat remains after significant weight loss.

#6 — AOD-9604: The Fat-Targeting GH Fragment

AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of the human growth hormone molecule — specifically amino acids 176–191 of the HGH C-terminus. It was originally developed by Monash University (Australia) as a targeted lipolytic agent that retains the fat-burning properties of full GH without its anabolic, glucose-elevating, or IGF-1-stimulating effects. This makes it uniquely fat-specific: it tells adipocytes to release stored fat without driving muscle growth or blood sugar disruption.

AOD-9604 passed human safety trials without significant adverse effects and achieved GRAS (Generally Recognized as Safe) status from the FDA in 2014 as a food supplement ingredient — an unusual regulatory milestone for a research peptide. While a pivotal obesity RCT failed to demonstrate significant weight loss on its own (partly due to low doses used), a substantial body of researcher-reported and clinical data consistently shows meaningful fat loss at the 300–500 mcg/day dosing range.

AOD-9604 Dosage

Standard protocol: 300–500 mcg subcutaneous injection daily, ideally in a fasted state in the morning. Often cycled 5 days on / 2 days off. Best results when combined with intermittent fasting or a controlled caloric deficit. Use our dose calculator for weight-adjusted starting doses.

Pros & Cons

• ✅ Fat-specific action — no blood glucose or IGF-1 elevation
• ✅ Excellent safety profile — GRAS status from FDA
• ✅ No muscle wasting concerns
• ✅ Well-tolerated, minimal side effects reported
• ❌ Modest fat loss on its own — best as a stack component
• ❌ No large-scale human RCT demonstrating weight loss (pivotal trial underpowered)
• ❌ Daily injections required

Best for: Body recomposition-focused users who want fat loss without any anabolic signaling. Excellent as part of a stack with CJC-1295 + Ipamorelin, or for individuals who cannot use GLP-1 drugs due to contraindications. Often used in the final phase of a cut to strip residual subcutaneous fat.

#7 — BPC-157: The Metabolic Support Peptide

BPC-157 (Body Protection Compound 157) ranks last on this list not because it's ineffective, but because its mechanism is fundamentally different from every other peptide here. It doesn't directly drive lipolysis or suppress appetite. Instead, it operates through the gut-brain axis, modulating dopamine and serotonin signaling, reducing gut inflammation, healing intestinal lining, and normalizing the neurological reward pathways that drive compulsive eating and metabolic dysregulation.

Think of BPC-157 as the foundation peptide that makes all the others work better. Users running GLP-1 drugs often stack BPC-157 to manage GI side effects (nausea, gastroparesis, reflux). Athletes using CJC-1295 + Ipamorelin add it for tendon, muscle, and recovery optimization. Its metabolic benefits — improved insulin sensitivity, reduced gut permeability, systemic anti-inflammatory action — create an indirect but meaningful environment for fat loss.

BPC-157 Dosage

Injectable protocol: 250–500 mcg subcutaneous injection once or twice daily. Oral/capsule protocol: 250–500 mcg orally twice daily (effective for gut healing; some systemic absorption). No standardized titration. Cycles of 6–12 weeks with 4-week breaks are common.

Pros & Cons

• ✅ Excellent GI side-effect mitigation when stacked with GLP-1 peptides
• ✅ Supports gut microbiome health and intestinal integrity
• ✅ Normalizes dopamine — reduces food cravings at a neurological level
• ✅ Available in oral form (no injection required for gut-focused use)
• ❌ No direct, large-scale human weight loss data
• ❌ Fat loss is indirect — not a primary weight-loss tool
• ❌ Research compound; regulatory status varies by country

Best for: Stacking with GLP-1 drugs to reduce GI side effects and improve tolerability, or as foundational metabolic support in any peptide protocol. Also recommended for anyone with gut dysbiosis, leaky gut, or inflammatory bowel conditions that may be undermining their metabolic health.

How to Choose the Right Peptide for Your Weight Loss Goal

No peptide is universally best. Your choice should be driven by your starting point, goals, and access:

Use the PeptideDeck dose calculator to build a personalized protocol based on your weight, goals, and experience level.

Stacking Protocols: Combining Peptides for Greater Effect

Advanced users often combine peptides from different mechanistic categories for synergistic fat loss. Here are three evidence-informed stacking approaches:

Stack A: GLP-1 + Gut Support (Best for GLP-1 Side Effect Mitigation)

• Semaglutide 2.4 mg (once weekly) OR Tirzepatide 10–15 mg (once weekly)
• BPC-157: 250–500 mcg daily (subcutaneous or oral)
• Goal: Maximize GLP-1 efficacy while protecting GI function and reducing nausea

Stack B: GH Secretagogue + Fat-Targeted (Best for Body Recomposition)

• CJC-1295 (without DAC): 200 mcg + Ipamorelin 200 mcg — 5× weekly before sleep
• AOD-9604: 400 mcg — daily, fasted morning injection
• Goal: Stimulate GH-driven fat oxidation while targeting residual subcutaneous fat

Stack C: Visceral Fat Protocol (Best for Metabolic Syndrome)

• Semaglutide 1.0–2.4 mg (once weekly) for appetite control and total weight reduction
• Tesamorelin: 2 mg (once daily) for visceral adipose tissue reduction
• BPC-157: 250 mcg (once daily) for metabolic and gut support
• Goal: Attack visceral fat from two independent axes — GLP-1 and GHRH

Important: Do not stack GLP-1 agonists from the same class (e.g., semaglutide + tirzepatide). Retatrutide should be used as a monotherapy — its triple agonism is already the most comprehensive multi-pathway approach available. See our full fat loss peptide guide for additional stacking protocols and cycling strategies.

Realistic Weight Loss Timeline: What to Expect

Frequently Asked Questions

What is the most effective peptide for weight loss in 2026?

Retatrutide is the most effective peptide for weight loss by clinical data, producing an average 28.7% body-weight reduction in phase 2 trials. Among FDA-approved options, tirzepatide (Zepbound) leads at ~20.9%, followed by semaglutide (Wegovy) at ~14.9%.

Are weight loss peptides safe?

FDA-approved peptides like semaglutide and tirzepatide have robust safety data from large-scale trials and real-world use. Common side effects include nausea, vomiting, and diarrhea, which typically improve after the titration phase. Research peptides like CJC-1295, AOD-9604, and BPC-157 have smaller safety datasets but favorable profiles in available studies. Always consult a licensed physician before starting any peptide protocol.

Can you use peptides for weight loss without injections?

Most weight-loss peptides require subcutaneous injection for full bioavailability. BPC-157 is the main exception — oral capsule formulations show meaningful efficacy for gut-related applications. Oral semaglutide (Rybelsus, 14 mg) is FDA-approved for diabetes but not explicitly for weight loss, and its bioavailability is lower than injectable Wegovy.

How long do you need to take weight loss peptides?

GLP-1 drugs (semaglutide, tirzepatide) show progressive weight loss over 48–72 weeks before plateauing. Most patients require ongoing maintenance dosing to preserve results — weight typically returns within 12 months of discontinuation without significant lifestyle changes. Research peptides like CJC-1295 + Ipamorelin are typically cycled (12 weeks on, 4 weeks off).

What's the difference between GLP-1 peptides and GH secretagogues for fat loss?

GLP-1 peptides (semaglutide, tirzepatide, retatrutide) primarily suppress appetite and slow gastric emptying, producing large-scale caloric restriction. GH secretagogues (CJC-1295, Ipamorelin, Tesamorelin) increase growth hormone pulsatility, driving direct lipolysis and lean mass preservation with less appetite effect. GLP-1 drugs produce faster, more dramatic weight loss; GH secretagogues are better for body recomposition without significant caloric restriction.

Can you stack semaglutide with CJC-1295 + Ipamorelin?

Yes — combining a GLP-1 drug with a GH secretagogue stack is one of the more sophisticated protocols used by physicians in weight management and anti-aging contexts. The GLP-1 drives caloric restriction and fat mass reduction while the GH secretagogues preserve lean mass. Discuss this combination with a physician to ensure it aligns with your metabolic goals and health history.

Is Retatrutide available yet?

Retatrutide is currently in phase 3 clinical trials (the TRIUMPH program) as of 2026. It is not yet FDA-approved. It may be available through clinical trial participation, international clinics, or research-compound suppliers. FDA approval is anticipated in 2026–2027 if phase 3 results mirror phase 2 findings. See our Retatrutide dosing guide for the latest sourcing and protocol information.